July 23, 2022
1 min watch
Save
VIDEO: CST fluctuations not common with Port Delivery System with ranibizumab
NEW YORK — In this Healio Video Perspective from the ASRS meeting, Veeral S. Sheth, MD, MBA, FASRS, FACS, discusses phase 3 results from the Archway trial.
The trial examined central subfield thickness fluctuations in patients with neovascular age-related macular degeneration treated with the Port Delivery System with ranibizumab, now known as Susvimo.
Published by:
Sources/Disclosures
Collapse
Source:
Sheth VS, et al. Central subfield thickness fluctuations and their impact on vision outcomes over 96 weeks in the Archway trial of the PDS. Presented at: American Society of Retina Specialists annual meeting; July 13-16, 2022; New York.
Disclosures:
Sheth reports consulting for Genentech/Roche.
Read more about